PACCAR INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PACCAR INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.44B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $33.66B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $35.13B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $28.82B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $23.52B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $18.73B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $25.60B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $23.50B | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $19.46B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $17.03B | Feb 21, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $17.12B | Feb 27, 2014 |
| FY2012 | Dec 31, 2012 | $17.05B | Feb 27, 2013 |
| FY2011 | Dec 31, 2011 | $16.36B | Feb 29, 2012 |
| FY2010 | Dec 31, 2010 | $10.29B | Mar 1, 2011 |
| FY2010 | Dec 31, 2009 | $8.09B | Mar 1, 2011 |
| FY2010 | Dec 31, 2008 | $14.97B | Mar 1, 2011 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.38B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $4.16B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $4.60B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $3.01B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $1.87B | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | $405.80M | Feb 17, 2021 |
| FY2020 | Sep 30, 2020 | $385.50M | Feb 17, 2021 |
| FY2020 | Jun 30, 2020 | $147.70M | Feb 17, 2021 |
| FY2020 | Mar 31, 2020 | $359.40M | Feb 17, 2021 |
| FY2020 | Dec 31, 2019 | $531.30M | Feb 17, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $445.50M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $452.90M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $410.90M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $341.20M | Feb 19, 2025 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $735.80M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $744.00M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $753.30M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $726.30M | Feb 19, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.42B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $4.64B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $4.19B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $3.03B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $2.19B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $2.99B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $2.86B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $2.99B | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $2.72B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $2.30B | Feb 21, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $743.00M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $838.70M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $695.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $525.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $559.10M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $550.40M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $574.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $457.60M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $423.40M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $375.20M | Feb 21, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.34B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $43.42B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $40.82B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $33.28B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $29.51B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $28.45B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $28.36B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $25.48B | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $23.44B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $20.64B | Feb 21, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.26B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $17.51B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $15.88B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $13.17B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $11.59B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $10.53B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $9.71B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $8.59B | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $8.05B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $6.78B | Feb 21, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.20M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $100.70M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $107.40M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $104.10M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $110.60M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $118.80M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $109.10M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $112.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $117.40M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $103.00M | Feb 21, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.70B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $17.75B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $15.78B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $13.40B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $12.03B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $11.01B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $10.40B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $9.28B | Feb 19, 2020 |
| FY2018 | Jan 1, 2018 | $8.39B | Feb 21, 2019 |
| FY2018 | Dec 31, 2017 | $8.37B | Feb 21, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $3.44B | Feb 21, 2019 |
| FY2017 | Dec 31, 2017 | $2.36B | Feb 21, 2018 |
| FY2016 | Dec 31, 2016 | $1.92B | Feb 21, 2017 |
| FY2015 | Dec 31, 2015 | $2.02B | Feb 16, 2016 |
| FY2014 | Dec 31, 2014 | $1.74B | Feb 26, 2015 |
| FY2013 | Dec 31, 2013 | $1.75B | Feb 27, 2014 |
| FY2012 | Dec 31, 2012 | $1.27B | Feb 27, 2013 |
| FY2011 | Dec 31, 2011 | $2.11B | Feb 29, 2012 |
| FY2010 | Dec 31, 2010 | $2.04B | Mar 1, 2011 |
| FY2009 | Dec 31, 2009 | $1.91B | Feb 26, 2010 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 7 | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 8 | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 17, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Feb 17, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 17, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 17, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 17, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 7 | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 8 | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 17, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Feb 17, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 17, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 17, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 17, 2021 |